Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With SLE
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs INV 103 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Invion
- 31 Aug 2018 Biomarkers information updated
- 08 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.